Hosted on MSN2mon
Teva inks partnership with Klinge to launch Eylea biosimilar in Europe
Teva is already marketing our FYB201 ranibizumab biosimilar (Ranivisio ® /Ongavia ®) in Europe and can synergistically leverage an existing commercial infrastructure..." In return, Klinge will ...
Business Insider25d
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
“In addition to Ongavia ® 3, our successful ranibizumab biosimilar in the UK, AHZANTIVE ® will provide a new, cost-efficient treatment option for patients with severe retinal ...
WebMD1mon
FDA OKs First Fast-Acting Insulin Biosimilar for Diabetes
Feb. 20, 2025 -- The FDA has approved a new fast-acting insulin biosimilar to help manage blood sugar in people with diabetes, including children and adults. The product, called Merilog ...
PharmiWeb25d
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Concurrently, Formycon had concluded an agreement with Teva for product supply. Teva is already marketing Formycon’s FYB201 ranibizumab Biosimilar (Ongavia ®) in the UK and can synergistically ...